Stable hypertensive patient who is administering ARB after renal transplant
Conditions
Interventions
Telmisartan-preceding group: Previous ARB is switched to equivalent amount of telmisartan without washout period and then telmisartan is administered with once-daily dosing for 12 weeks. After 12 wee
Sponsors
Department of Surgery and Oncology Graduate School of Medical Sciences Kyushu University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patient who passed six months or more after renal transplant and patients to whom the dosages of calcineurin inhibitor (tacrolimus or cyclosporine), antimetabolic drug (mycophenolate mofetil or mizoribine) and steroid are steady 2.Stable hypertensive patient (less than BP 130/80) on antihypertensive with an angiotensin II receptor blocker 3.Gender free, and from 20 years old to less than 75 years old 4.Patient who obtained written informed consent
Exclusion criteria
Exclusion criteria: 1.Ptient with graft loss 2.Patient who has a history of hypersensitivity 3.Patient who is pregnant or a female patient who is expecting to become pregnant 4.Patient with extremely bad secretion of bile (total bilirubin: >= 2.0 mg/dL) 5.Patient who has serious hepatic disorder (GOT or GPT: >= 100 IU/L) 6.Patient who has serious renal disorder (serum creatinine: >= 3.0 mg/dL) 7.Patient with hyperkalemia (K: >= 5.5 mEq/L) 8.Patient who is currently receiving pioglitazone 9.Patient who is currently receiving angiotensin converting enzyme inhibitor 10.Patient who is currently receiving lipid-lowering therapy with fibrate agent 11.Patient who began taking statin within two months before start of the study 12.Patient with whom the physician-in-charge considered inappropriate as a subject of the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in serum triglyceride level and adiponectin level from baseline to 12 weeks after | — |
Secondary
| Measure | Time frame |
|---|---|
| Casual blood pressure, fasting blood glucose, HbA1c, glycoalbumin, fasting insulin, HOMA-IR (calculation from blood glucose level and insulin level), LDL-C, HDL-C, serum creatinine, eGFR (calculation from serum creatinine level), urinary albumin-to-creatinine ratio, adverse event | — |
Countries
Japan
Contacts
Public Contactyoshifumi miura
medical faculty of Kyushu university Department of Surgery and Oncology
Outcome results
None listed